<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00715611</url>
  </required_header>
  <id_info>
    <org_study_id>08-053</org_study_id>
    <nct_id>NCT00715611</nct_id>
  </id_info>
  <brief_title>Pleurectomy/Decortication (Neo) Adjuvant Chemotherapy and Intensity Modulated Radiation Therapy to the Pleura in Patients With Locally Advanced Malignant Pleural Mesothelioma</brief_title>
  <official_title>Phase II Toxicity Study of Pleurectomy/Decortication, (Neo) Adjuvant Chemotherapy and Intensity Modulated Radiation Therapy to the Pleura in Patients With Locally Advanced Malignant Pleural Mesothelioma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Princess Margaret Hospital, Canada</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <brief_summary>
    <textblock>
      For patients with this type of cancer, the standard of care is treatment with chemotherapy.
      Radiation therapy is typically not used. This is because radiation to the entire lining of
      the lung has many side effects that are often severe including damage to the lung
      (pneumonitis). There is a new radiation technique using Intensity Modulated Radiation Therapy
      (IMRT) that has been shown to reduce many of the side effects of standard radiation therapy.
      This type of radiation therapy specifically targets the lining of the lung, where you have
      your cancer, and reduces the risk of damaging the lung itself. The purpose of this study is
      to test the safety and implementation of standard pleurectomy/decortication (removal of the
      surface lining of the lung) and standard chemotherapy followed by IMRT performed at other
      centers. Patients will undergo pleurectomy/decortication chemotherapy and hemithoracic
      pleural IMRT to the pleura in patients with malignant pleural mesothelioma.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 11, 2008</start_date>
  <completion_date type="Anticipated">July 2020</completion_date>
  <primary_completion_date type="Anticipated">July 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>number of patients ≥ grade 3 pneumonitis</measure>
    <time_frame>2 years</time_frame>
    <description>Grade 3 pneumonitis is defined as symptomatic, interfering with ADL's and requiring oxygen support as defined by the NCI Common Terminology Criteria (CTC) version 4.0 for toxicity and Adverse Event reporting.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">81</enrollment>
  <condition>Mesothelioma</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This is a multicenter phase II toxicity study of pleurectomy/decortication (P/D) followed by adjuvant chemotherapy and Intensity Modulated Radiation Therapy (IMRT) to the pleura in patients with malignant pleural mesothelioma. Alternatively, chemotherapy may be administered in the neoadjuvant setting prior to P/D, followed by IMRT. Patients deemed resectable at the time of enrollment will undergo P/D with the goal of a macroscopic complete resection (MCR). Those with disease progression or severe toxicity will stop chemotherapy and undergo a PET scan.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Pleurectomy/Decortication</intervention_name>
    <description>Pleurectomy/decortication will be performed as per standard technique</description>
    <arm_group_label>1</arm_group_label>
    <other_name>(P/D)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pemetrexed and cisplatin or carboplatin</intervention_name>
    <description>The combination of pemetrexed and cisplatin or carboplatin will be given every 3 weeks for up to 4 cycles. Pemetrexed will be administered at 500mg/m2 as a 10-minute infusion. Cisplatin will be administered at 75mg/m2 as a 60-minute infusion. Carboplatin will be administered at an AUC of 5 over 30 minutes. Chemotherapy may be administered in the neoadjuvant or adjuvant setting.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Intensity Modulated Radiation Therapy</intervention_name>
    <description>IMRT will be administered over approximately 6 weeks at 50.4 Gy in 28 fractions with an optional SIB to gross residual disease (pending meeting normal tissue constraints).</description>
    <arm_group_label>1</arm_group_label>
    <other_name>IMRT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provide written informed consent to participate on the study

          -  Patients must have a pathologically confirmed diagnosis either at MSKCC or at the
             participating site of stage I-III malignant pleural mesothelioma

          -  Epithelioid or biphasic histology subtype (Note: patients with biphasic histology can
             have &lt; 10% sarcomatoid)

          -  No evidence of metastatic disease.

          -  Patient age ≥ 18 years but ≤ 80 years at the time of consent.

          -  Karnofsky performance status ≥ 80%

          -  Pulmonary Function Tests:

               1. For all patients: DLCO &gt; 40% predicted (corrected for Hgb)

               2. For patients enrolled post-P/D, only: FEV1 &gt;/= 35% (corrected for Hgb) (Note:
                  patients enrolled prior to P/D will have PFTs repeated pre-IMRT. If this criteria
                  is not met, they will be removed from study)

          -  In cases of concern about decreased renal function and potential high radiation dose
             to the kidneys, an optional nuclear medicine kidney function scan may be performed
             prior to radiation therapy to determine the functional contribution of each kidney.

          -  Patient enrolled prior to chemotherapy must have adequate organ function as indicated
             by the following laboratory values:

               1. Absolute neutrophil count ≥1.5 K/mcL

               2. Platelets ≥100 K/mcL

               3. Serum total bilirubin ≤ 1.5 X ULN

               4. AST (SGOT) or ALT (SGPT) ≤ 3.0 X ULN Note: patients enrolled after chemotherapy
                  do not have to meet the above criteria

        Exclusion Criteria:

          -  &gt; 10% Sarcomatoid or desmoplastic histology

          -  Continuous oxygen use

          -  Prior nephrectomy on the contralateral side of MPM

          -  Prior intrapleural therapy (except pleurodesis) or intrapleural therapy at the time of
             P/D (i.e.: intrapleural chemotherapy, photodynamic therapy, intrapleural betadine)

          -  Prior thoracic radiation therapy preventing hemithoracic pleural IMRT

          -  Bulky disease in the fissure preventing lung-sparing pleural IMRT

          -  Patients undergoing extrapleural pneumonectomy

          -  Patients with an active infection that require systemic antibiotics, antiviral, or
             antifungal treatments

          -  Patients with a concurrent active malignancy (except squamous or basal cell carcinoma
             of the skin)

          -  Patients with serious unstable medical illness

          -  Presence of third space fluid that cannot be controlled by drainage

          -  For patients who develop or have baseline clinically significant pleural effusions
             before or during initiation of pemetrexed therapy; consideration should be given to
             drain the effusion prior to chemotherapy administration

          -  No acute congestive heart failure

          -  Pregnant or lactating women

          -  Men or women not using effective contraception

        Reproductive risks Patients should not become pregnant or father a baby while on this study
        because the drugs in this study can affect an unborn baby. Women should not breast-feed a
        baby while on this study. Women of childbearing age will be counseled to use birth control
        while on this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andreas Rimner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andreas Rimner, MD</last_name>
    <phone>212-639-6025</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Valerie Rusch, MD</last_name>
    <phone>212-639-5873</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bradford Perez, MD</last_name>
      <phone>888-663-3488</phone>
    </contact>
    <investigator>
      <last_name>Bradford Perez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raymond Mak, MD</last_name>
      <phone>617-632-3591</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Cancer Center</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nina Garces, MD</last_name>
      <phone>507-538-3270</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering at Basking Ridge</name>
      <address>
        <city>Basking Ridge</city>
        <state>New Jersey</state>
        <zip>07920</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Rimner, MD</last_name>
      <phone>212-639-6025</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Monmouth</name>
      <address>
        <city>Middletown</city>
        <state>New Jersey</state>
        <zip>07748</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Rimner, MD</last_name>
      <phone>212-639-6025</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Bergen</name>
      <address>
        <city>Montvale</city>
        <state>New Jersey</state>
        <zip>07645</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Rimner, MD</last_name>
      <phone>212-639-6025</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center @ Suffolk</name>
      <address>
        <city>Commack</city>
        <state>New York</state>
        <zip>11725</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Rimner, MD</last_name>
      <phone>212-639-6025</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering West Harrison</name>
      <address>
        <city>Harrison</city>
        <state>New York</state>
        <zip>10604</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Rimner, MD</last_name>
      <phone>212-639-6025</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Rimner, MD</last_name>
      <phone>212-639-6025</phone>
    </contact>
    <contact_backup>
      <last_name>Valerie Rusch, MD</last_name>
      <phone>212-639-5873</phone>
    </contact_backup>
    <investigator>
      <last_name>Andreas Rimner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering at Mercy Medical Center</name>
      <address>
        <city>Rockville Centre</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Rimner, MD</last_name>
      <phone>212-639-6025</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center at Phelps Memorial Hospital Center</name>
      <address>
        <city>Sleepy Hollow</city>
        <state>New York</state>
        <zip>10591</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Rimner, MD</last_name>
      <phone>212-639-6025</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Md Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Gomez, MD</last_name>
    </contact>
    <investigator>
      <last_name>Daniel Gomez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mskcc.org</url>
    <description>Memorial Sloan-Kettering Cancer Center</description>
  </link>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>July 11, 2008</study_first_submitted>
  <study_first_submitted_qc>July 14, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 15, 2008</study_first_posted>
  <last_update_submitted>August 6, 2019</last_update_submitted>
  <last_update_submitted_qc>August 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 7, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pemetrexed</keyword>
  <keyword>cisplatin</keyword>
  <keyword>IMRT</keyword>
  <keyword>PLEURA</keyword>
  <keyword>Malignant</keyword>
  <keyword>08-053</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mesothelioma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

